Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 May-Jun;48(3):318-20.
doi: 10.4103/0253-7613.182894.

Black hairy tongue with a fixed dose combination of olanzapine and fluoxetine

Ratinder Jhaj  1 , Pushp Raj Gour  1 , Dinesh Prasad Asati  2
Affiliations

Black hairy tongue with a fixed dose combination of olanzapine and fluoxetine

Ratinder Jhaj et al. Indian J Pharmacol. 2016 May-Jun.

Abstract

Black hairy tongue (BHT) is a benign disease characterized by elongated filiform lingual papillae, with a carpet-like appearance of the dorsum of the tongue. It is has been reported to occur with a prevalence ranging from 0.6% to 11.3%. Although its etiology is not fully understood, BHT may be triggered by smoking, excessive coffee or black tea drinking, poor oral hygiene, trigeminal neuralgia, general debilitation, dry mouth as well as certain drugs. We present here a case of a patient with psychosis, depression, and benign prostatic hyperplasia, who developed BHT following treatment with a fixed dose combination (FDC) of olanzapine and fluoxetine and recovered within 3 months after withdrawal of treatment with FDC.

Keywords: Black hairy tongue; filiform papillae; fluoxetine; olanzapine.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Appearance of the tongue at the time of presentation
Figure 2
Figure 2
Appearance of the tongue three months after withdrawal of olanzapine and fluoxetine
See this image and copyright information in PMC

References

    1. Gurvits GE, Tan A. Black hairy tongue syndrome. World J Gastroenterol. 2014;20:10845–50. - PMC - PubMed
    1. Yadav AK, Jeenger J, Panwar D. Evaluation of rationality of fixed-dose combinations prescribed in psychiatric patients. Natl J Physiol Pharm Pharmacol. 2016;6:150–4.
    1. Conley RR, Meltzer HY. Adverse events related to olanzapine. J Clin Psychiatry. 2000;61(Suppl 8):26–9. - PubMed
    1. Verma P, Praharaj SK, Arya SC, et al. Stomatitis associated with olanzapine and sodium valproate combination treatment. Ger J Psychiatry. 2005;8:27–8.
    1. Gordon M, Melvin G. Selective serotonin re-uptake inhibitors – A review of the side effects in adolescents. Aust Fam Physician. 2013;42:620–3. - PubMed

Supplementary concepts